Treatment Approaches for R/R Follicular Lymphoma in the 3L and Beyond

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

At a median follow-up of 17.0 months, the sintilimab/chidamide regimen elicited 1-year PFS and OS rates of 95.7% and 95.3%, respectively.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Treatment with KITE-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.

Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.